ALBIREO PHARMA, INC.
已退市CIK 1322505fmd_18M4A8800XD614PP9JM5V6WNR0制造业 · 医药制剂模板: 标准
覆盖范围: 2004年10月01日 至 2022年9月30日，共 55 个期间
| 项目 | FY2014 | FY2015 | FY2015 | FY2016 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | – | 0 | 13 | 10 | 8 | 41 |
| 净利息收入 | – | – | (2) | – | (1) | 0 | (5) | (5) | – | – |
| 营业成本 | – | – | – | – | – | – | – | – | – | 1 |
| 毛利润 | – | – | – | – | – | – | – | – | 8 | 39 |
| 研发费用 | 14 | 13 | – | – | 8 | 13 | 32 | 46 | 77 | 83 |
| 销售、一般及管理费用 | – | – | – | – | – | – | – | – | 42 | 70 |
| 营业费用合计 | 19 | 20 | – | – | 24 | 25 | 51 | 71 | 105 | 163 |
| 营业利润 | – | – | (5) | – | (12) | (25) | (38) | (61) | (96) | (123) |
| 利息及投资收益 | 0 | 0 | – | 0 | – | – | – | – | – | – |
| 其他营业外收入（支出） | – | – | (0) | – | (3) | 0 | (3) | 4 | – | – |
| 税前利润 | (14) | – | (7) | – | (16) | (24) | (46) | (63) | (108) | (34) |
| 所得税费用 | 0 | 0 | – | – | 0 | 0 | 0 | – | – | – |
| 持续经营净利润 | (14) | – | (7) | – | (16) | (24) | (46) | – | – | – |
| 净利润 | (14) | (19) | – | – | (16) | (24) | (46) | (63) | (108) | (34) |
| 归属于普通股股东的净利润 | – | – | – | – | – | – | – | (63) | (108) | (34) |